Danisco announced the completion of a study by Griffith University in Australia on the use of their patented probiotic Bifidobacteriumlactis BI-04 physically active adults. The study found that there was a reduction in the incidence, duration and severity of cold or upper respiratory tract illness when the subjects received Bifidobacteriumlactis BI-04. The degree of illness and medication were also reduced. The volunteers for the trial had reductions in upper respiratory tract illness of 30-50%.
This was the first study that looked at healthy populations while others have looked at people whose immune systems were either in the decline – such as the elderly – or developing – such as children.
David Pyne of the Australian Institute of Sport said, “The results are impressive when you consider the likely magnitude of clinical benefits to physically active individuals.” Peter Fricker stated, “These findings, which demonstrate benefit in healthy individuals, hold promise for other groups in the population who may be more susceptible to respiratory infections such as the young and elderly.”
This is not the first study in which Bifidobacteriumlactis BI-04 has been shown to be helpful in keeping people healthy. For many of us it may be a good choice as a daily probiotic.